DE1147580B - Process for the preparation of 5, 6-dichloro-3, 17ª ‡ -dihydroxy-16ª ‰ -methyl-allopregnan-20-one or of its 3-acylates - Google Patents

Process for the preparation of 5, 6-dichloro-3, 17ª ‡ -dihydroxy-16ª ‰ -methyl-allopregnan-20-one or of its 3-acylates

Info

Publication number
DE1147580B
DE1147580B DEM42887A DEM0042887A DE1147580B DE 1147580 B DE1147580 B DE 1147580B DE M42887 A DEM42887 A DE M42887A DE M0042887 A DEM0042887 A DE M0042887A DE 1147580 B DE1147580 B DE 1147580B
Authority
DE
Germany
Prior art keywords
methyl
dichloro
allopregnan
dihydroxy
acylates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DEM42887A
Other languages
German (de)
Inventor
Meyer Sletzinger
Donald Floyd Reinhold
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of DE1147580B publication Critical patent/DE1147580B/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)

Description

Verfahren zur Herstellung von 5, 6-Dichlor-3,17 a-dihydroxy-16ß-methyl-allopregnan-20-on bzw. von dessen 3-Acylaten Die Erfindung betrifft ein Verfahren zur Herstellung von 5,6-Dichlor-3,17x-dihydroxy-16ß-methyl-allopregnan-20-on bzw. von dessen 3-Acylaten, welches darin besteht, daß man einen niederen aliphatischen Carbonsäureester des 5,6-Dichlor-3-hydroxy-16,17-oxido-16ß-methyl-allopregnan-20-ons (I) mit einer starken Säure behandelt, das erhaltene Gemisch von 5,6-Dichlor-3,17x-dihydroxy-16-methyl-15(16)-allopregnen-20-on (II) und 5,6-Dichlor-3,17a-dihydroxy-16-methylen-allopregnan-20-on (IIA) in an sich bekannter Weise katalytisch hydriert und das erhaltene 5,6-Dichlor-3,17x-dihydroxy-16ß-methyl-allopregnan-20-on (11I) gewünschtenfalls nach an sich bekannten Methoden in ein entsprechendes 3-Acylat (IV) überführt.Process for the preparation of 5, 6-dichloro-3,17 a-dihydroxy-16β-methyl-allopregnan-20-one or of its 3-acylates. The invention relates to a process for the preparation of 5,6-dichloro-3,17x-dihydroxy-16ß-methyl-allopregnan-20-one or of its 3-acylates, which consists in having a lower aliphatic carboxylic acid ester of the 5,6-dichloro-3-hydroxy-16,17-oxido-16ß-methyl-allopregnan-20-ons (I) with a strong Treated acid, the resulting mixture of 5,6-dichloro-3,17x-dihydroxy-16-methyl-15 (16) -allopregnen-20-one (II) and 5,6-dichloro-3,17a-dihydroxy-16-methylen-allopregnan-20-one (IIA) in itself catalytically hydrogenated in a known manner and the resulting 5,6-dichloro-3,17x-dihydroxy-16ß-methyl-allopregnan-20-one (11I) if desired into a corresponding 3-acylate by methods known per se (IV) transferred.

Die Umsetzungen verlaufen nach dem folgenden Formelschema In den obigen Strukturformeln bedeutet R den Rest einer niederen aliphatischen Carbonsäure und R' einen Acylsubstituenten. Der Ausgangsstoff des erfindungsgemäßen Verfahrens kann folgendermaßen hergestellt werden: Ein 3-Acyloxy-5,16-pregnadien-20-on wird in einem organischen Lösungsmittel mit Diazomethan zu 3-Acyloxy-16a,17x-methylenazo-5-pregnen-20-on umgesetzt. Diese Verbindung bildet beim Erhitzen 3-Acyloxy-16ß-methyl-5,16-pregnadien-20-on, welches mit einer alkoholischen Alkalilauge zu 3-Hydroxy-16ß-methyl-5,16-pregnadien-20-on hydrolysiert wird. Die letztere Verbindung geht durch Oxydation mit Wasserstoffperoxyd oder einer Persäure in 3-Hydroxy-16,17-oxido-16-methyl-5-pregnen-20-on über, welches zu einem 3-Acyloxy-16,17-oxido-16-methyl-5-pregnen-20-on acyliert wird. Letzteres wird dann durch Umsetzung mit Chlor in einem organischen Lösungsmittel in den verfahrensgemäß eingesetzten Ausgangsstoff, nämlich ein 5,6-Dichlor-3-acyloxy-16,17-oxido-16ßmethyl-allopregnan-20-on, überführt.The conversions proceed according to the following equation In the structural formulas above, R denotes the radical of a lower aliphatic carboxylic acid and R 'denotes an acyl substituent. The starting material for the process according to the invention can be prepared as follows: A 3-acyloxy-5,16-pregnadien-20-one is reacted with diazomethane in an organic solvent to give 3-acyloxy-16a, 17x-methylenazo-5-pregnen-20-one . When heated, this compound forms 3-acyloxy-16ß-methyl-5,16-pregnadien-20-one, which is hydrolyzed with an alcoholic alkali to 3-hydroxy-16ß-methyl-5,16-pregnadien-20-one. The latter compound goes over by oxidation with hydrogen peroxide or a peracid in 3-hydroxy-16,17-oxido-16-methyl-5-pregnen-20-one, which leads to a 3-acyloxy-16,17-oxido-16- methyl-5-pregnen-20-one is acylated. The latter is then converted into the starting material used according to the process, namely a 5,6-dichloro-3-acyloxy-16,17-oxido-16ßmethyl-allopregnan-20-one, by reaction with chlorine in an organic solvent.

Für die beschriebene Herstellung dieses Ausgangsstoffes wird hier Patentschutz nicht beansprucht.For the production of this starting material described here Patent protection not claimed.

Im einzelnen wird das erfindungsgemäße Verfahren folgendermaßen durchgeführt: Das 3-Acyloxy-5,6-dichlor-16ß-methyl-16a, 17xoxido-allopregnan-20-on wird durch Behandlung mit einer starken Säurewie Perchl orsäure, in ein Gemisch der Verbindungen 5,6-Dichlor-3,17a-dihydroxy-16-methyl-15(16)-allopregnen-20-on und 5,6-Dichlor-3,17a-dihydroxy-16-methylen-allopregnan-20-on übergeführt, die beide eine Doppelbindung in 16-Stellung enthalten. Die Hydrierung dieses Gemisches mit Wasserstoff in Gegenwart eines Hydrierungskatalysators, wie Platinoxyd, führt zur Bildung von 5,6-Dichlor-3,17x-dihydroxy-16ß-methyl-allopregnan-20-on als Hauptprodukt, welches gegebenenfalls in bekannter Weise mit einem Carbonsäureanhydrid, wie Essigsäureanhydrid, in Pyridin zu einem entsprechenden 3-Acylat, z. B. 5,6-Dichlor-3-acetoxy-17x-hydroxy-16ß-methyl-allopregnan-20-on, umgesetzt wird.In detail, the method according to the invention is carried out as follows: The 3-acyloxy-5,6-dichloro-16ß-methyl-16a, 17xoxido-allopregnan-20-one is through Treatment with a strong acid such as perchloric acid in a mixture of the compounds 5,6-dichloro-3,17a-dihydroxy-16-methyl-15 (16) -allopregnen-20-one and 5,6-dichloro-3,17a-dihydroxy-16-methylene-allopregnan-20-one transferred, both of which contain a double bond in the 16-position. The hydrogenation this mixture with hydrogen in the presence of a hydrogenation catalyst such as Platinum oxide, leads to the formation of 5,6-dichloro-3,17x-dihydroxy-16ß-methyl-allopregnan-20-one as the main product, which may be mixed in a known manner with a carboxylic acid anhydride, such as acetic anhydride, in pyridine to a corresponding 3-acylate, e.g. B. 5,6-dichloro-3-acetoxy-17x-hydroxy-16ß-methyl-allopregnan-20-one, is implemented.

Die erfindungsgemäß hergestellten Verbindungen sind Zwischenprodukte für die Herstellung hochaktiver entzündungshemmender Steroide, wie llß,17.x,21-Trihydroxy-16ß-methyl-4-pregnen-3,20-dion und l 1ß,17x, 21-Trihydroxy-16ß-methyl-1,4-pregnadien-3,20-dion.The compounds prepared according to the invention are intermediates for the production of highly active anti-inflammatory steroids such as llß, 17.x, 21-trihydroxy-16ß-methyl-4-pregnen-3,20-dione and l 1β, 17x, 21-trihydroxy-16β-methyl-1,4-pregnadiene-3,20-dione.

Zu diesem Zweck kann das 5,6-Dichlor-3,17a-dihydroxy-16ß-methyl-allopregnan-20-on über eine entsprechende 21-Halogenverbindung zu 5,6-Dichlor-17xhydroxy-21-acyloxy-16ß-methyl-allopregnan-20-on umgesetzt werden. Diese Verbindung bildet bei der Chlorabspaltung 3,17a-Dihydroxy-21-acyloxy-16ß-methyl-4-pregnen-20-on, welches zu 17oc-Hydroxy-21-acyloxy-16ß-methyl-4-pregnen-3,20-dion oxydiert wird. Letzteres kann durch 1(2)-Dehydrierung in 17a-Hydroxy-21-acyloxy-16ß-methyl-1,4-pregnädien-3,20-dion übergeführt werden. In die beiden zuletzt genannten Verbindungen kann eine 21-ständige Hydroxylgruppe eingeführtwerden.Das soerhaltene 17a,21-Dihydroxy-16ßmethyl-4-pregnen-3,20-dion bzw. 17a,21-Dihydroxy-16ß-methyl-1,4-pregnadien-3,20-dion wird auf mikrobiologischem Wege unter Bildung von hochaktiven Verbindungen, wie l 1ß,17x,21-Trihydroxy-16ß-methyl-4-pregnen-3,20-dion und llß,17n,21-Trihydroxy-16ßmethyl-1,4-pregnadien-3,20-dion in 11-Stellung hydroxyliert. Beispiel Eine Lösung von 2,0 g 5,6-Dichlor-3-acetoxy-16,17-oxido-16ß-methyl-allopregnan-20-on in 75 ml Dioxan und 20m1 2 n-Perchlorsäure wird 48 Stunden bei Zimmertemperatur gerührt. Das Gemisch wird mit dem gleichen Volumen Wasser verdünnt und der Niederschlag abfiltriert und gründlich mit Wasser gewaschen. Zur Entfernung eines in geringer Menge gebildeten UV-absorbierenden Nebenproduktes wird das Gemisch aus 5,6-Dichlor-3,17ca-dihydroxy-16-methyl-15(16)-allopregnen-20-on und 5,6-Dichlor-3,17a-dihydroxy-16-methylen-allopregnan-20-on aus Methanol-Petroläther umkristallisiert. Der Schmelzpunkt des Gemisches beträgt nach dieser Behandlung 194 bis 198° C (unter Zersetzung). Die optische Drehung des Gemisches beträgt -114° (CHC13).For this purpose, the 5,6-dichloro-3,17a-dihydroxy-16ß-methyl-allopregnan-20-one via a corresponding 21-halogen compound to 5,6-dichloro-17xhydroxy-21-acyloxy-16β-methyl-allopregnan-20-one implemented. When chlorine is split off, this compound forms 3,17a-dihydroxy-21-acyloxy-16ß-methyl-4-pregnen-20-one, which is oxidized to 17oc-hydroxy-21-acyloxy-16β-methyl-4-pregnen-3,20-dione. The latter can be converted into 17a-hydroxy-21-acyloxy-16ß-methyl-1,4-pregnadien-3,20-dione by 1 (2) -dehydrogenation be transferred. In the two last-mentioned connections a 21-digit The thus obtained 17a, 21-dihydroxy-16β-methyl-4-pregnen-3,20-dione or 17a, 21-dihydroxy-16ß-methyl-1,4-pregnadiene-3,20-dione is microbiological Pathways with the formation of highly active compounds such as l 1ß, 17x, 21-trihydroxy-16ß-methyl-4-pregnen-3,20-dione and 11β, 17n, 21-trihydroxy-16β-methyl-1,4-pregnadiene-3,20-dione hydroxylated in the 11-position. Example A solution of 2.0 g of 5,6-dichloro-3-acetoxy-16,17-oxido-16β-methyl-allopregnan-20-one in 75 ml of dioxane and 20m1 2 n-perchloric acid is 48 hours at room temperature touched. The mixture is diluted with an equal volume of water and the precipitate filtered off and washed thoroughly with water. To remove one in less Amount of UV-absorbing by-product formed is the mixture of 5,6-dichloro-3,17ca-dihydroxy-16-methyl-15 (16) -allopregnen-20-one and 5,6-dichloro-3,17a-dihydroxy-16-methylene-allopregnan-20-one from methanol-petroleum ether recrystallized. The melting point of the mixture is after this treatment 194 to 198 ° C (with decomposition). The optical rotation of the mixture is -114 ° (CHC13).

Ein Gemisch von 1 g dieser beiden ungesättigten Verbindungen wird bei 2,7 at an 0,12 g Platinoxydkatalysator in 25 ml gereinigtem Dioxan hydriert. Der Katalysator wird zunächst in dem Dioxan vorreduziert. Nach Absorption der theoretischen Menge Wasserstoff wird die Hydrierung abgebrochen und der Katalysator abfiltriert. 100 ml Wasser fällen das Produkt, 5,6-Dichlor-3,17x-dihydroxy-16ß-methyl-allopregnan-20-on, aus, das abfiltriert und gewaschen wird. Fp. =198 bis 202° C. Durch Umkristallisieren aus Aceton steigt der Schmelzpunkt auf 207 bis 209° C. [x] ö5 = 69° C, c = 1 (CHC13).A mixture of 1 g of these two unsaturated compounds is hydrogenated at 2.7 atm over 0.12 g of platinum oxide catalyst in 25 ml of purified dioxane. The catalyst is first pre-reduced in the dioxane. After the theoretical amount of hydrogen has been absorbed, the hydrogenation is terminated and the catalyst is filtered off. 100 ml of water precipitate the product, 5,6-dichloro-3,17x-dihydroxy-16β-methyl-allopregnan-20-one, which is filtered off and washed. Mp = 198 to 202 ° C. Recrystallization from acetone increases the melting point to 207 to 209 ° C. [x] δ5 = 69 ° C., c = 1 (CHCl3).

Das Produkt wird mittels Essigsäureanhydrid und Pyridin in die 3-Acetoxyverbindung übergeführt.The product is converted into the 3-acetoxy compound using acetic anhydride and pyridine convicted.

Claims (1)

PATENTANSPRUCH: Verfahren zur Herstellung von 5,6-Dichlor-3,17x-dihydroxy-16ß-methyl-allopregnan-20-on bzw. von dessen 3-Acylaten, dadurch gekennzeichnet, daß man einen niederen aliphatischen Carbonsäureester des 5,6-Dichlor-3-hydroxy-16,17-oxido-16ßmethyl-allopregnan-20-ons mit einer starken Säure behandelt, das erhaltene Gemisch von 5,6-Dichlor-3,17x-dihydroxy-16-methyl-15(16)-allopregnen-20-on und 5,6-Dichlor-3,17x-dihydroxy-16-methylen-allopregnan-20-on in an sich bekannter Weise katalytisch hydriert und das erhaltene 5,6-Dichlor-3,17x-dihydroxy-16ß-methyl-allopregnan-20-on gewünschtenfalls mit einem Carbonsäureanhydrid nach an sich bekannten Methoden in ein entsprechendes 3-Acylat überführt.PATENT CLAIM: Process for the production of 5,6-dichloro-3,17x-dihydroxy-16ß-methyl-allopregnan-20-one or of its 3-acylates, characterized in that a lower aliphatic Carboxylic acid ester of 5,6-dichloro-3-hydroxy-16,17-oxido-16β-methyl-allopregnan-20-one treated with a strong acid, the resulting mixture of 5,6-dichloro-3,17x-dihydroxy-16-methyl-15 (16) -allopregnen-20-one and 5,6-dichloro-3,17x-dihydroxy-16-methylene-allopregnan-20-one in known per se Wise catalytically hydrogenated and the resulting 5,6-dichloro-3,17x-dihydroxy-16ß-methyl-allopregnan-20-one if desired with a carboxylic anhydride by methods known per se in a corresponding 3-acylate transferred.
DEM42887A 1958-10-01 1959-09-28 Process for the preparation of 5, 6-dichloro-3, 17ª ‡ -dihydroxy-16ª ‰ -methyl-allopregnan-20-one or of its 3-acylates Pending DE1147580B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1147580XA 1958-10-01 1958-10-01

Publications (1)

Publication Number Publication Date
DE1147580B true DE1147580B (en) 1963-04-25

Family

ID=22357250

Family Applications (1)

Application Number Title Priority Date Filing Date
DEM42887A Pending DE1147580B (en) 1958-10-01 1959-09-28 Process for the preparation of 5, 6-dichloro-3, 17ª ‡ -dihydroxy-16ª ‰ -methyl-allopregnan-20-one or of its 3-acylates

Country Status (1)

Country Link
DE (1) DE1147580B (en)

Similar Documents

Publication Publication Date Title
DE1147580B (en) Process for the preparation of 5, 6-dichloro-3, 17ª ‡ -dihydroxy-16ª ‰ -methyl-allopregnan-20-one or of its 3-acylates
DE932798C (en) Process for the production of steroid epoxies
DE1807585C3 (en) 14,15beta-epoxy cardenolides, processes for their preparation and compositions containing them
DE1199262C2 (en) Process for the preparation of 5alpha-bromo-6beta-hydroxysteroids
DE957661C (en) Process for the preparation of 17-oxy-20-keto-21acyl-oxypregnanes
DE955504C (en) Process for the preparation of 17 ª ‡ -oxy-20-keto-21-acyloxysteroids
DE1593505C3 (en)
CH500958A (en) Process for making steroid compounds
DE1643017C3 (en) Process for the preparation of e-chloro-1,2alpha-methylene-delta nor 4,6-pregnadienes
AT257060B (en) Process for the preparation of new 3-enol ethers of the 6-methyl-3-oxo-Δ <4> -steroids of the androstane, 19-norandrostane, pregnane and 19-norpregnane series
DE2017533C3 (en) New carbonate esters of 6alpha, 9alpha-difluoro-11beta, 16alpha, 17alpha, 21-tetrahydroxy-pregna-1,4-diene-3,20dione-16alpha-17alpha-acetonide, processes for their preparation and agents containing them
DE956955C (en) Process for the preparation of pregnan-and allopregnan-3ª ‡ -o1-11, 20-dione or of allopregnan-3ª ‰, 11ª ‡ diol-20-one
AT248039B (en) Process for the preparation of 17α-acyloxy-21-hydroxy-steroids
DE1047199B (en) Process for the preparation of a 17 ‡, 21-dioxy or 17 ‡ -oxy-21-acyloxy-1,4-pregnadiene-3,20-dione
DE1183079B (en) Process for the preparation of saturated 4-hydroxy-3-keto-5alpha-steroids
DE1105412B (en) Process for the preparation of ?-3-keto-6ª‡-methylsteroids of the androstane and pregnane series
CH329201A (en) Process for the preparation of 4,17(20)-3-keto-steroid-21-acid alkyl esters
CH336822A (en) Process for the preparation of 17a-oxy-20-keto-21-acyloxy-steroids
DE1113453B (en) Process for the production of substitution products of Reichsteins-Substance-S or their 21-acylates
CH339924A (en) Process for the preparation of 17-oxy-20-keto-21-acyloxysteroids of the pregnan or allopregnan series
DE1171424B (en) Process for the preparation of 6ª ‰ -fluoro-5ª ‡ -hydroxysteroids of the pregnan or androstane series
DE1117118B (en) Process for the preparation of 20-monoenol acylates of 11, 20-diketosteroids
DE1793670A1 (en) Steroids and their method of manufacture
DE1193041B (en) Process for making delta 7, delta 7.9, (11), delta 7.9, (11), 16, delta 7, delta 8 or delta 8.16 steroids
DEU0003322MA (en)